Evidence map›Paper›PMID 38466021›Full record

ArticleCancer medicine2024

Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening.

Sara Nofal, Jiangong Niu, Paul Resong, Jeff Jin, Kelly W Merriman, Xiuning Le, Hormuzd Katki, John Heymach, Mara B Antonoff, Edwin Ostrin and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Sara NofalDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-8966-2056
Jiangong NiuDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Paul ResongDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeff JinInformation Services, Enterprise Development and Integration, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kelly W MerrimanDepartment of Tumor Registry, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xiuning LeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hormuzd KatkiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland, USA.
John HeymachDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mara B AntonoffDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Edwin OstrinDepartment of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jia WuDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jianjun ZhangDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Iakovos ToumazisDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-3462-2137
The University of Texas MD Anderson Cancer Center · USNational Institutes of Health · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
CANCER PREVENTION EDUCAT--STUDENT RESEARCH EXPERIENCESR25CA056452 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Shine Chang · 1992 to 2026
$6.9M
Optimizing Personalized Screening and Diagnostic Decisions for Lung Cancer Based on Dynamic Risk Assessment and Life ExpectancyR37CA271187 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Iakovos Toumazis · 2022 to 2026
$2.8M
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinomaR01CA234629 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZHANG, JIANJUN · 2019 to 2023
$1.8M
NCI NIH HHS P30 CA016672NCI NIH HHS P30CA016672NCI NIH HHS R01 CA234629NCI NIH HHS R25 CA056452NCI NIH HHS R25ECA056452NCI NIH HHS R37 CA271187
6 · The paper itself

Abstract

backgroundPersonal history of cancer is an independent risk factor for lung cancer but is omitted from existing lung cancer screening eligibility criteria. In this study, we assess the lung cancer risk among cancer survivors and discuss potential implications for screening.

methodsThis was a retrospective, secondary analysis of data from the Surveillance, Epidemiology and End Results (SEER) registry and the MD Anderson Cancer Center (MDACC). We estimated the standardized incidence ratios (SIRs) for lung cancer by site of first primary cancer using data from SEER. We assessed the lung cancer risk among head and neck cancer survivors from MDACC using cumulative incidence and compared the risk ratios (RR) by individuals' screening eligibility status.

resultsOther than first primary lung cancer (SIR: 5.10, 95% CI: 5.01-5.18), cancer survivors in SEER with personal history of head and neck cancer (SIR: 3.71, 95% CI: 3.63-3.80) had the highest risk of developing second primary lung cancer, followed by bladder (SIR: 1.86, 95% CI: 1.81-1.90) and esophageal cancers (SIR: 1.78, 95% CI: 1.61-1.96). Head and neck cancer survivors had higher risk to develop lung cancer compared to the National Lung Screening Trial's subjects, (781 vs. 572 per 100,000 person-years, respectively). Head and neck cancer survivors ineligible for lung cancer screening seen at MDACC had significantly higher lung cancer risk than head and neck cancer survivors from SEER (RR: 1.9, p < 0.001).

conclusionPersonal history of cancer, primarily head and neck cancer, is an independent risk factor for lung cancer and may be considered as an eligibility criterion in future lung cancer screening recommendations.

Indexed as

Esophageal NeoplasmsLung NeoplasmsNeoplasms, Second PrimaryEarly Detection of CancerHumansLungRetrospective StudiesRisk Factorscancer survivorhead and neck cancerlung cancer screeningpersonal history of cancerrisk assessmentSecond primary lung cancer

Identifiers

PMID38466021
PMCPMC10926882
OpenAlexW4392651613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.